High-energy ball milling of saquinavir increases permeability across the buccal mucosa.
Saquinavir (SQV), a candidate for buccal drug delivery, is limited by poor solubility. This study identified the effects of high-energy ball milling on the buccal permeability of SQV and compared it to the effects of chemical enhancers, i.e. ethylenediaminetetraacetic acid (EDTA), sodium lauryl sulfate (SLS), polyethylene glycol (PEG) and beta cyclodextrin (β-cyclodextrin). SQV was ball milled using a high energy planetary mill (1, 3, 15 and 30 h) and permeation studies across porcine buccal mucosa were performed using franz diffusion cells. Drug was quantified by UV spectrophotometry. Both unmilled and milled SQV samples were able to permeate the buccal mucosa. Milled samples of 15 h displayed the greatest flux of 10.40 ± 1.24 µg/cm(2 )h and an enhancement ratio of 2.61. All enhancers were able to increase the buccal permeability of unmilled SQV, with SLS achieving the greatest flux (6.99 ± 0.7 µg/cm(2)) and an enhancement ratio of 1.75. However, all the milled SQV samples displayed greater permeability than SLS, the best chemical enhancer for unmilled SQV. Enhanced permeability by ball milling was attributed to reduction in particle size, formation of solid dispersions and an increase in solubility of milled samples. Microscopical evaluation revealed no significant loss in mucosal cellular integrity treated with either unmilled or milled SQV. Histological studies suggest that SQV uses both the paracellular and transcellular route of transport across the mucosa, with drug treatment having no permanent affects. High-energy ball milling was superior to the chemical enhancers studied for enhancement of SQV buccal permeation.
Department of Pharmaceutical Sciences, University of KwaZulu-Natal , Durban , South Africa and.
Sanjeev
S
Rambharose
Elizabeth
E
Ojewole
Michael
M
Branham
Rahul
R
Kalhapure
Thirumala
T
Govender
D000278:Administration, Buccal; D000818:Animals; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D046529:Microscopy, Electron, Transmission; D009061:Mouth Mucosa / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D065568:Oral Mucosal Absorption; D010539:Permeability; D019258:Saquinavir / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D012967:Sodium Dodecyl Sulfate; D012995:Solubility; D013501:Surface-Active Agents; D034421:Sus scrofa
D004304:Dosage Forms; D017320:HIV Protease Inhibitors; D013501:Surface-Active Agents; D012967:Sodium Dodecyl Sulfate; D019258:Saquinavir